Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bioverse vs Omada Health

Bioverse
Graded #231

Higher grade

vs+9.399999999999999
Omada Health
Graded #436

Lower grade

The verdict

Bioverse takes it — 65/100 to 55.6/100.

Bioverse grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bioverse (GoBioverse) offers compounded semaglutide and tirzepatide plus brand-name Ozempic, Wegovy, and Mounjaro.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBioverse +22
67
45
Dose & formulationBioverse +37
77
40
Clinical oversightOmada Health +3
74
77
Labs & monitoringOmada Health +8
53
61
FulfillmentEven
62
62
Contract termsOmada Health +22
33
55
Bioverse · left barOmada Health · right bar

The numbers

MetricBioverseOmada Health
WeighScore65/10055.6/100
GradeCC
Scorecard rank#231#436
Semaglutide$129/mo (starting dose, compounded)Not disclosed
Tirzepatide$399/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Bioverse

Graded #231 · C

Strengths

  • Wide formulary — compounded and brand-name semaglutide + tirzepatide plus metformin
  • No membership, cancellation, doctor, or hidden fees
  • Uses US-licensed, FDA-regulated pharmacies

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • State availability not disclosed beyond 'a provider licensed in your state'
  • Broader longevity platform (NAD+, B12, glutathione, hair, skincare, heart health) rather than GLP-1 focused
Omada Health

Graded #436 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard